Method of Eradicating Ticks That Attach to Humans Using Lotilaner Formulations
Summary
USPTO published patent application US20260108498A1 filed December 22, 2025 (Application No. 19429133) for methods of treating or preventing Lyme disease and other vector-borne diseases via administration of lotilaner, an isoxazoline anti-parasitic therapeutic agent. The application discloses formulations and dosing regimens for eradicating ticks that attach to humans. Named inventors are Bobak Robert Azamian, Douglas Michael Ackermann, Christopher Stivers, and Shawn D. Hickok. CPC classifications indicate pharmaceutical compositions (A61K 31/422, A61K 9/08, A61K 47/26) and antiparasitic applications (A61P 33/14).
“Disclosed herein are methods of treating or preventing vector-borne diseases including Lyme disease via delivery of one, two, or more systemic doses of an isoxazoline anti-parasitic therapeutic agent to an individual with confirmed or suspected infestation of Lyme disease.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
USPTO published patent application US20260108498A1 covering methods of treating or preventing vector-borne diseases including Lyme disease by administering one or more systemic doses of lotilaner, an isoxazoline anti-parasitic therapeutic agent, to individuals with confirmed or suspected tick infestation. The application discloses pharmaceutical formulations and dosing protocols for tick eradication in humans.
Affected parties include pharmaceutical companies developing antiparasitic therapeutics, biotech firms researching Lyme disease treatments, and vector-borne disease treatment developers. This patent application, if granted, could claim priority in the isoxazoline-based tick eradication space. Competitors developing similar anti-parasitic formulations for Lyme disease or other tick-borne illnesses should monitor this application's prosecution for potential freedom-to-operate implications.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD OF ERADICATING TICKS THAT ATTACH TO HUMANS USING LOTILANER FORMULATIONS
Application US20260108498A1 Kind: A1 Apr 23, 2026
Inventors
Bobak Robert Azamian, Douglas Michael Ackermann, Christopher Stivers, Shawn D. Hickok
Abstract
Disclosed herein are methods of treating or preventing vector-borne diseases including Lyme disease via delivery of one, two, or more systemic doses of an isoxazoline anti-parasitic therapeutic agent to an individual with confirmed or suspected infestation of Lyme disease.
CPC Classifications
A61K 31/422 A61K 9/08 A61K 47/26 A61P 33/14
Filing Date
2025-12-22
Application No.
19429133
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.